ATE239468T1 - Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen - Google Patents

Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen

Info

Publication number
ATE239468T1
ATE239468T1 AT97907822T AT97907822T ATE239468T1 AT E239468 T1 ATE239468 T1 AT E239468T1 AT 97907822 T AT97907822 T AT 97907822T AT 97907822 T AT97907822 T AT 97907822T AT E239468 T1 ATE239468 T1 AT E239468T1
Authority
AT
Austria
Prior art keywords
carbonanhydrase
inhibitors
macular edema
treat macular
treat
Prior art date
Application number
AT97907822T
Other languages
English (en)
Inventor
William Eric Sponsel
Alon Harris
Original Assignee
Advanced Res & Tech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9605642.9A external-priority patent/GB9605642D0/en
Application filed by Advanced Res & Tech Inst filed Critical Advanced Res & Tech Inst
Application granted granted Critical
Publication of ATE239468T1 publication Critical patent/ATE239468T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eye Examination Apparatus (AREA)
AT97907822T 1996-02-26 1997-02-25 Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen ATE239468T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1225096P 1996-02-26 1996-02-26
GBGB9605642.9A GB9605642D0 (en) 1996-03-18 1996-03-18 Treatment of macular edema
PCT/US1997/002874 WO1997030704A2 (en) 1996-02-26 1997-02-25 Use of carbonic anhydrase inhibitors for treating macular edema

Publications (1)

Publication Number Publication Date
ATE239468T1 true ATE239468T1 (de) 2003-05-15

Family

ID=26308946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97907822T ATE239468T1 (de) 1996-02-26 1997-02-25 Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen

Country Status (26)

Country Link
EP (1) EP0954305B9 (de)
JP (1) JP4392481B2 (de)
KR (1) KR100471586B1 (de)
CN (1) CN1225582A (de)
AT (1) ATE239468T1 (de)
AU (1) AU727565B2 (de)
BG (1) BG64525B1 (de)
BR (1) BR9707674A (de)
CA (1) CA2247063C (de)
CZ (1) CZ299509B6 (de)
DE (1) DE69721824T2 (de)
DK (1) DK0954305T3 (de)
EA (1) EA001681B1 (de)
EE (1) EE03804B1 (de)
ES (1) ES2199348T4 (de)
HU (1) HU227161B1 (de)
IL (1) IL125912A0 (de)
IS (1) IS2053B (de)
MX (1) MXPA98006961A (de)
NO (1) NO320043B1 (de)
NZ (1) NZ331843A (de)
PT (1) PT954305E (de)
SK (1) SK284371B6 (de)
TR (1) TR199801665T2 (de)
WO (1) WO1997030704A2 (de)
YU (1) YU49422B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9716657D0 (en) 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
EP1058546A4 (de) * 1998-03-06 2004-07-28 Univ Texas Zusammenstellungen und methoden zur behandlung von erkrankungen der macula
US5948801A (en) * 1998-03-09 1999-09-07 Alcon Laboratories, Inc. Treatment of retinal edema with brinzolamide
CA2336703A1 (en) * 1998-07-10 2000-01-20 The University Of Sydney Prophylactic treatments of neovascularisation in macular degeneration
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
CA2671137A1 (en) 2006-12-15 2008-06-26 Nicox S.A. Carbonic anhydrase inhibitors derivatives
AR084194A1 (es) * 2010-12-09 2013-04-24 Fovea Pharmaceuticals Derivados de arilsulfonamida para la prevencion o el tratamiento de trastornos oftalmologicos especificos
JP2020504711A (ja) 2016-12-21 2020-02-13 バイオセリックス, インコーポレイテッド タンパク質を標的とすることにおいて使用するための、チエノピロール誘導体、その組成物、方法、および使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797413A (en) * 1986-05-14 1989-01-10 Merck & Co., Inc. Thieno thiopyran sulfonamide derivatives, pharmaceutical compositions and use
GB2223166B (en) * 1988-09-29 1992-03-18 American Cyanamid Co Stable ophthalmic preparations containing methazolamide
US5153192A (en) * 1990-04-09 1992-10-06 Alcon Laboratories, Inc. Thiophene sulfonamides useful as carbonic anhydrase inhibitors

Also Published As

Publication number Publication date
ES2199348T4 (es) 2010-10-19
AU727565B2 (en) 2000-12-14
BG64525B1 (bg) 2005-06-30
DE69721824D1 (de) 2003-06-12
NZ331843A (en) 2000-09-29
YU49422B (sh) 2006-01-16
YU35398A (sh) 2001-12-26
TR199801665T2 (xx) 1998-12-21
IS4829A (is) 1998-08-20
BR9707674A (pt) 2000-01-04
EE03804B1 (et) 2002-08-15
AU1972197A (en) 1997-09-10
DK0954305T3 (da) 2003-08-25
EA001681B1 (ru) 2001-06-25
CN1225582A (zh) 1999-08-11
HUP9902054A3 (en) 2001-07-30
CA2247063A1 (en) 1997-08-28
JP2000506833A (ja) 2000-06-06
SK284371B6 (sk) 2005-02-04
KR19990087242A (ko) 1999-12-15
IS2053B (is) 2005-10-14
HU227161B1 (en) 2010-09-28
NO983906L (no) 1998-10-19
SK115198A3 (en) 2000-01-18
EP0954305B9 (de) 2010-08-04
BG102797A (en) 1999-09-30
EE9800263A (et) 1999-08-16
MXPA98006961A (es) 2004-11-19
CA2247063C (en) 2004-01-06
PT954305E (pt) 2003-09-30
DE69721824T2 (de) 2004-03-11
EP0954305A2 (de) 1999-11-10
EA199800764A1 (ru) 1999-06-24
KR100471586B1 (ko) 2005-07-11
WO1997030704A2 (en) 1997-08-28
WO1997030704A3 (en) 1997-09-25
HUP9902054A1 (hu) 2000-03-28
CZ269998A3 (cs) 2000-01-12
ES2199348T3 (es) 2004-02-16
JP4392481B2 (ja) 2010-01-06
EP0954305B1 (de) 2003-05-07
NO320043B1 (no) 2005-10-17
IL125912A0 (en) 1999-04-11
NO983906D0 (no) 1998-08-25
CZ299509B6 (cs) 2008-08-20

Similar Documents

Publication Publication Date Title
DE69721824D1 (de) Verwendung von carbonanhydrase-hemmern zur behandlung von makulär-ödemen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69428813D1 (de) Verwendung von Botulinustoxin zur Behandlung von Spannungs-Kopfschmerz
ATE298566T1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE292462T1 (de) Behandlung von asthma anhand von mek-inhibitoren
ATE207356T1 (de) Verwendung von tiagabin zur behandlung von schlafstörungen
ATE258989T1 (de) Verfahren zur verflüssigung von stärke
ATE473753T1 (de) Verwendung von botulinum toxin zur behandlung von post-operative schmerzen
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
ATE196847T1 (de) Verwendung von mannosephosphaten zur behandlung von fibrotischen störungen
DE69424537D1 (de) Therapeutischer wirkstoff zur behandlung von melanomen
ATE156358T1 (de) Verfahren zur behandlung von androgener lopecia mit 5-alpha-reduktase-hemmern
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE293455T1 (de) Knollen- oder wurzel-gewonnene proteaseinhibitoren zur vorbeugung oder behandlung von entzündung oder pruritus
DE69727695D1 (de) Verwendung von matrix-metalloproteinase inhibitoren zur förderung der wundheilung
ATE218330T1 (de) Verwendung von transglutaminasehemmer zur behandlung des narbegewebes
DE69814444D1 (de) Kombination von angiotensing-convertin-enzyme hemmern mit diuretikum zur behandlung von störungen der mikrozirkulation
UA66757C2 (en) Ophthalmologic composition of carbonic anhydrase inhibitors, method for treating or preventing macular edema or age-related macular degeneration
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
EE9700350A (et) COMT-inhibiitorite uus kasutamine ja diabeetiliste vaskulaarsete häirete ärahoidmise meetod
EP1009421A4 (de) Verfahren und zusammenstellungen zur verbesserten wundheilung
RU94042315A (ru) Способ лечения язвенной болезни желудка и двенадцатиперстной кишки
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
ATE311190T1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
NO984198L (no) FremgangsmÕte for behandling av aggresjon

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0954305

Country of ref document: EP

REN Ceased due to non-payment of the annual fee